SYH2056

Primary objectives: (1) To evaluate the safety and tolerability of a single oral dose of SYH2056 tablets in healthy subjects and its effects on neuropsychiatric status; (2) To evaluate the pharmacokinetic effects of a single oral dose of SYH2056 tablets in healthy subjects under fasting conditions; (3) To evaluate the effects of food on the pharmacokinetics of SYH2056 tablets in healthy subjects. Secondary objectives: (1) To conduct a preliminary study on the metabolic transformation of a single oral dose of SYH2056 tablets in healthy subjects under fasting conditions; (2) To evaluate the effects of a high-fat diet on the safety of SYH2056 tablets in healthy subjects; (3) To evaluate the potential hallucinogenicity, subjective drug preference, and early dependence signals of a single oral dose of SYH2056 tablets in healthy subjects.